InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR).
Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.
Location: France, Pays de la Loire, Nantes
Employees: 1-10
Total raised: $6.819661M
Founded date: 2013
Investors 1
Date | Name | Website |
- | GO Capital... | gocapital.... |
Funding Rounds 1
Date | Series | Amount | Investors |
03.06.2016 | Series A | $6.819661M | - |
Mentions in press and media 3
Date | Title | Description | Source |
10.01.2022 | InFlectis BioScience Receives Approval from French Regulator... | Nantes, France--(Newsfile Corp. - January 10, 2022) - InFlectis BioScience SAS, a clinical-stage com... | marketscre... |
04.10.2021 | InFlectis BioScience Expands Leadership Team with Three Expe... | Nantes, France--(Newsfile Corp. - October 4, 2021) - InFlectis BioScience SAS, a clinical-stage comp... | marketscre... |
03.06.2016 | Biopharmaceutical Company InFlectis BioScience Raises €6M in... | InFlectis BioScience SAS, a Nantes, France-based biopharmaceutical company specializing in the disco... | finsmes.co... |